Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by therapy for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announces the co-optation of Dr. Lucy Lu as a director on its Board of Directors, effective of November 9, 2022, in place of Sofinnova Partners.
The appointment of Dr. Lucy Lu will be submitted to the shareholders for ratification at the next Inventiva General Meeting.